000071172 001__ 71172 000071172 005__ 20240111111736.0 000071172 0247_ $$2doi$$a10.1111/ajt.14996 000071172 0248_ $$2sideral$$a106894 000071172 037__ $$aART-2018-106894 000071172 041__ $$aeng 000071172 100__ $$aManzardo, C 000071172 245__ $$aDirect-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. 000071172 260__ $$c2018 000071172 5060_ $$aAccess copy available to the general public$$fUnrestricted 000071172 5203_ $$aDirect-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV-RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P = .239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P = .093) and genotype 4 (P = .088) was observed. In conclusion, interferon-free regimens with DAAs for post-LT recurrence of HCV infection in HIV-infected individuals were highly effective and well tolerated, with results comparable to those of HCV-monoinfected patients. 000071172 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/ 000071172 590__ $$a7.163$$b2018 000071172 591__ $$aTRANSPLANTATION$$b2 / 25 = 0.08$$c2018$$dQ1$$eT1 000071172 591__ $$aSURGERY$$b5 / 203 = 0.025$$c2018$$dQ1$$eT1 000071172 592__ $$a3.2$$b2018 000071172 593__ $$aImmunology and Allergy$$c2018$$dQ1 000071172 593__ $$aTransplantation$$c2018$$dQ1 000071172 593__ $$aPharmacology (medical)$$c2018$$dQ1 000071172 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000071172 700__ $$aLondoño, MC 000071172 700__ $$aCastells, L 000071172 700__ $$aTestillano, M 000071172 700__ $$aMontero, JL 000071172 700__ $$aPeñafiel, J 000071172 700__ $$aSubirana, M 000071172 700__ $$aMoreno, A 000071172 700__ $$aAguilera, V 000071172 700__ $$aGonzález-Diéguez, ML 000071172 700__ $$aCalvo-Pulido, J 000071172 700__ $$aXiol, X 000071172 700__ $$aSalcedo, M 000071172 700__ $$aCuervas-Mons, V 000071172 700__ $$aSousa, JM 000071172 700__ $$aSuarez, F 000071172 700__ $$0(orcid)0000-0002-7119-2244$$aSerrano, T$$uUniversidad de Zaragoza 000071172 700__ $$aHerrero, JI 000071172 700__ $$aJiménez, M 000071172 700__ $$aFernandez, JR 000071172 700__ $$aGiménez, C 000071172 700__ $$adel Campo, S 000071172 700__ $$aEsteban-Mur, JI 000071172 700__ $$aCrespo, G 000071172 700__ $$aMoreno, A 000071172 700__ $$ade la Rosa, G 000071172 700__ $$aRimola, A 000071172 700__ $$aMiro, JM 000071172 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000071172 773__ $$g18, 10 (2018), 2513-2522$$pAM J TRANSPLANT$$tAMERICAN JOURNAL OF TRANSPLANTATION$$x1600-6135 000071172 8564_ $$s463815$$uhttps://zaguan.unizar.es/record/71172/files/texto_completo.pdf$$yVersión publicada 000071172 8564_ $$s83485$$uhttps://zaguan.unizar.es/record/71172/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000071172 909CO $$ooai:zaguan.unizar.es:71172$$particulos$$pdriver 000071172 951__ $$a2024-01-11-10:59:16 000071172 980__ $$aARTICLE